Comparative Pharmacology
Head-to-head clinical analysis: SULSOXIN versus TRIPLE SULFAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSOXIN versus TRIPLE SULFAS.
SULSOXIN vs TRIPLE SULFAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Competitive inhibition of dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication. Triple sulfas (sulfadiazine, sulfamerazine, sulfamethazine) act synergistically to inhibit folic acid synthesis.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
1 to 2 tablets (each containing sulfadiazine 167 mg, sulfamerazine 167 mg, sulfamethazine 167 mg) orally every 4 hours initially, then 2 tablets every 6 hours. Maximum daily dose: 6 grams of total sulfonamide.
None Documented
None Documented
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Terminal elimination half-life ranges from 10-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours) and neonates (40-120 hours).
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Primarily renal; approximately 70-100% excreted unchanged in urine via glomerular filtration and tubular secretion. Minor biliary/fecal elimination (<5%) with enterohepatic circulation possible.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic